STRADIM is a closed-loop, patient-individualized platform that turns hyperthermal therapy into precision immuno-oncology. It continuously and gently warms a patient's blood extracorporeally while five integrated subsystems work in concert — monitoring biomarkers in real time, preserving key immune signals, activating a patient's own immune cells, and precisely timing immunotherapy delivery — all within a single treatment session.
Continuously samples blood and measures key immune and tumor markers in real time throughout treatment.
A two-stage process removes harmful metabolites while preserving the immune signals that drive anti-tumor response.
Activates a patient's own immune cells using tumor antigens harvested live during the same session.
A closed-loop control algorithm computes a real-time immunosensitization index to guide treatment.
Delivers immunotherapy agents at the biologically optimal moment identified by the platform's algorithm.
Hyperthermal therapy has decades of published clinical and scientific literature behind it. STRADIM™ builds on this foundation and adds closed-loop molecular control, immune cell priming, and precision-timed immunotherapy — each layer designed to extend and personalize the therapeutic benefit.
Sources: Overgaard J, et al., "Randomised Trial of Hyperthermia as Adjuvant to Radiotherapy for Recurrent or Metastatic Malignant Melanoma," The Lancet (1995); van der Zee J, et al., "Comparison of Radiotherapy Alone with Radiotherapy Plus Hyperthermia in Locally Advanced Pelvic Tumours," The Lancet (2000); Wust P, et al., "Hyperthermia in Combined Treatment of Cancer," The Lancet Oncology (2002); Issels RD, et al., "Neo-Adjuvant Chemotherapy Alone or with Regional Hyperthermia for Localised High-Risk Soft-Tissue Sarcoma," The Lancet Oncology (2010); "A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers," PMC (2022).